Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical…

Abstract

BackgroundRandomized trials show substantial weight loss with semaglutide and tirzepatide under structured care, but little is known about whether patients in routine practice continue therapy, reach a maintenance dose, and have their weight measured.

ObjectivesTo describe the first year after initiation of semaglutide or tirzepatide for obesity, including care patterns, maintenance-dose attainment, weight documentation, and total body weight loss (TBWL).

MethodsThis retrospective cohort study used Epic Cosmos, an electronic health record network of >350 US health systems, to identify adults with obesity and without diabetes who initiated injectable semaglutide or tirzepatide in 2024. Outcomes over 12 months included prescribing persistence, discontinuation, switching, add-on therapy, and reinitiation; attainment of Food and Drug Administration (FDA)-labeled maintenance doses; availability of follow-up weight; and TBWL across progressively restricted populations.

ResultsAmong 743,153 adults (60.1% semaglutide; mean age, 48.5 years; 72.5% female), 12-month prescribing persistence was 29.9% for semaglutide and 35.9% for tirzepatide. FDA-labeled maintenance-dose attainment was 28.3% and 55.0%, respectively, and only 8.8% and 16.4% remained prescribing persistent at a maintenance dose with a recorded weight at 12 months. About half of initiators lacked a 12-month weight. Among all initiators, [≥]5% TBWL was documented in 25.6% (semaglutide) and 30.4% (tirzepatide), rising to 51.9% and 61.9% among those with recorded weight, 66.1% and 79.5% among those also prescribing persistent, and 82.9% and 87.3% among those further at a maintenance dose.

ConclusionsIn routine practice, most patients initiating semaglutide or tirzepatide did not remain on therapy, reach a maintenance dose, and have weight documented through the first year. Documented weight loss was greatest among those completing each step of care, suggesting continuation, dose escalation, and monitoring as targets for improvement.

CENTRAL ILLUSTRATIONCare Cascade and Weight-Loss Outcomes Among Semaglutide and Tirzepatide Initiators, Standardized to 100 Initiators.

Numbers are per 100 initiators and were rounded so that categories at each step sum to the preceding step. At the 12-month dose step, prescribed dose was missing for 1 per 100 semaglutide initiators and <1 per 100 tirzepatide initiators.

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC="FIGDIR/small/26364715v1_ufig1.gif" ALT="Figure 1"> View larger version (27K): [email protected]@134de35org.highwire.dtl.DTLVardef@1e87ba1org.highwire.dtl.DTLVardef@cba45_HPS_FORMAT_FIGEXP M_FIG C_FIG

Changes in Eating Behavior and Food Preferences After Semaglutide or Tirzepatide Initiation: A Prospective Observational Pilot Study
Elisabetta Camajani, Francesco Frigerio, Chiara Quattrini +7
Nutrients5 Nov 2026Peer-reviewedCC BY 4.0NutritionCrossref
Safety Profile of Tirzepatide in Real‐World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database
Xinghua Guo, Jiahua Zhang, Qisen Li +2
Diabetes Obesity and Metabolism13 Jul 2026Peer-reviewedLicence not statedFull text6 citedPharmacology & toxicologyOpenAlex
Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review
Aditya K. Gupta, Elizabeth M. Teasell, Renata F. Magalhães +2
Medical sciences (Basel, Switzerland)1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Oral Semaglutide in Routine Clinical Practice: 24‐Month Real‐World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes
Maria Pompea Antonia Baldassarre, Giulia Di Dalmazi, Federica Carrieri +4
Diabetes, Obesity & Metabolism21 Sep 2026Peer-reviewedCC BY 4.0Full textEndocrinology & metabolismPMC
Atypical Anorexia Nervosa Developed in a Patient with Severe Obesity and Type 2 Diabetes Following Sleeve Gastrectomy and Postoperative Treatment with Semaglutide and Tirzepatide
Chiaki Saito, Masahiro Saito, Masatoshi Nakagawa +7
Internal Medicine1 Aug 2026Peer-reviewedCC BY-NC-NDFull textPsychiatry & mental healthJ-STAGE

Cite

BibTeX RIS

BibTeX

@misc{yang2026postinitiation,
  title = {{Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice}},
  author = {H. Yang and C. Kim and J. S. Ross and C. Huang and K. Choi and B. Kang and A. Arun and H. Tang and Y. Chen and H. Xu and M. Sharifi and Z. Li and H. Krumholz and Y. Lu},
  howpublished = {medRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.04.26364715},
  url = {https://www.medrxiv.org/content/10.64898/2026.10.04.26364715v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice
AU  - H. Yang
AU  - C. Kim
AU  - J. S. Ross
AU  - C. Huang
AU  - K. Choi
AU  - B. Kang
AU  - A. Arun
AU  - H. Tang
AU  - Y. Chen
AU  - H. Xu
AU  - M. Sharifi
AU  - Z. Li
AU  - H. Krumholz
AU  - Y. Lu
PY  - 2026
DA  - 2026/10/04
PB  - medRxiv
DO  - 10.64898/2026.10.04.26364715
UR  - https://www.medrxiv.org/content/10.64898/2026.10.04.26364715v1
AB  - BackgroundRandomized trials show substantial weight loss with semaglutide and tirzepatide under structured care, but little is known about whether patients in routine practice continue therapy, reach a maintenance dose, and have their weight measured.  ObjectivesTo describe the first year after initiation of semaglutide or tirzepatide for obesity, including care patterns, maintenance-dose attainment, weight documentation, and total body weight loss (TBWL).  MethodsThis retrospective cohort study used Epic Cosmos, an electronic health record network of >350 US health systems, to identify adults with obesity and without diabetes who initiated injectable semaglutide or tirzepatide in 2024. Outcomes over 12 months included prescribing persistence, discontinuation, switching, add-on therapy, and reinitiation; attainment of Food and Drug Administration (FDA)-labeled maintenance doses; availability of follow-up weight; and TBWL across progressively restricted populations.  ResultsAmong 743,153 adults (60.1% semaglutide; mean age, 48.5 years; 72.5% female), 12-month prescribing persistence was 29.9% for semaglutide and 35.9% for tirzepatide. FDA-labeled maintenance-dose attainment was 28.3% and 55.0%, respectively, and only 8.8% and 16.4% remained prescribing persistent at a maintenance dose with a recorded weight at 12 months. About half of initiators lacked a 12-month weight. Among all initiators, [≥]5% TBWL was documented in 25.6% (semaglutide) and 30.4% (tirzepatide), rising to 51.9% and 61.9% among those with recorded weight, 66.1% and 79.5% among those also prescribing persistent, and 82.9% and 87.3% among those further at a maintenance dose.  ConclusionsIn routine practice, most patients initiating semaglutide or tirzepatide did not remain on therapy, reach a maintenance dose, and have weight documented through the first year. Documented weight loss was greatest among those completing each step of care, suggesting continuation, dose escalation, and monitoring as targets for improvement.  CENTRAL ILLUSTRATIONCare Cascade and Weight-Loss Outcomes Among Semaglutide and Tirzepatide Initiators, Standardized to 100 Initiators.  Numbers are per 100 initiators and were rounded so that categories at each step sum to the preceding step. At the 12-month dose step, prescribed dose was missing for 1 per 100 semaglutide initiators and <1 per 100 tirzepatide initiators.  O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC="FIGDIR/small/26364715v1_ufig1.gif" ALT="Figure 1"> View larger version (27K): [email protected]@134de35org.highwire.dtl.DTLVardef@1e87ba1org.highwire.dtl.DTLVardef@cba45_HPS_FORMAT_FIGEXP M_FIG C_FIG
ER  -

Abstract

Related

Cite